Back to top
more

Moderna (MRNA)

(Real Time Quote from BATS)

$121.69 USD

121.69
1,173,558

+1.29 (1.07%)

Updated Jul 26, 2024 03:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Moderna (MRNA) Seeks FDA Nod for Updated COVID-19 Vaccine

by Zacks Equity Research

Moderna's (MRNA) updated COVID-19 vaccine is designed to target the XBB.1.5 sublineage. The company expects the vaccine to be available for the fall season, provided the FDA authorizes the same.

Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Moderna (MRNA) closed at $120.48, marking a -0.49% move from the previous day.

Sanghamitra Saha headshot

Biotech ETFs in Focus on Covid Vaccines' Fall Rollout

by Sanghamitra Saha

The FDA advised to Pfizer, Moderna and Novavax to manufacture single-strain jabs targeting the omicron subvariant XBB.1.5 should prove to be a victory for some biotech ETFs.

Moderna (MRNA) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed the most recent trading day at $128.73, moving -0.96% from the previous trading session.

FDA Panel Endorses Updating COVID Jab to Target XBB Strain

by Zacks Equity Research

An FDA panel unanimously recommends updating COVID vaccines to target one of the currently dominating XBB strains of the virus.

Company News for Jun 16, 2023

by Zacks Equity Research

Companies in The News Are: JD, KR, MRNA, JBL

Investors Heavily Search Moderna, Inc. (MRNA): Here is What You Need to Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Moderna (MRNA). This makes it worthwhile to examine what the stock has in store.

Axsome (AXSM) Soars 8.1%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Axsome (AXSM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed at $126.05 in the latest trading session, marking a -1.51% move from the prior day.

Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Moderna (MRNA) closed at $124.94, marking a -0.53% move from the previous day.

Vertex (VRTX) Stock Poised Well for Growth in 2023: Here's Why

by Zacks Equity Research

Vertex Pharmaceuticals (VRTX) stock is likely to be driven by several catalysts this year. Multiple clinical milestones are likely to be achieved in 2023 and 2024, both in its CF and non-CF portfolio.

Moderna (MRNA), Merck's Cancer Jab Delays Melanoma Spreading

by Zacks Equity Research

Updated data from a mid-stage study showed that Moderna (MRNA)/Merck's personalized cancer vaccine combined with Keytruda reduces the skin cancer's spreading by 65% in melanoma patients.

Here is What to Know Beyond Why Moderna, Inc. (MRNA) is a Trending Stock

by Zacks Equity Research

Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

EMA Panel Endorses Novavax's (NVAX) COVID Jab for Full Approval

by Zacks Equity Research

Novavax's (NVAX) protein-based COVID-19 vaccine gets recommendation for full marketing authorization in COVID-19 patients from European Medicines Agency.

Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RYH)?

by Zacks Equity Research

Sector ETF report for RYH

Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for RYH

Is Trending Stock Moderna, Inc. (MRNA) a Buy Now?

by Zacks Equity Research

Moderna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Moderna (MRNA) Posts Upbeat Data on Protein Replacement Therapy

by Zacks Equity Research

Interim data from a study shows that Moderna's (MRNA) investigational therapy for propionic acidemia (PA) exhibited early signs of dose-dependent pharmacology and potential clinical benefits.

Here's Why Merck (MRK) Stock Has Outperformed Industry YTD

by Zacks Equity Research

Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments should keep Merck's (MRK) stock afloat in 2023.

Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Moderna (MRNA) Q1 Earnings & Sales Top Estimates, Stock Up 2%

by Zacks Equity Research

Moderna (MRNA) beats expectations for both earnings and sales. The company posts higher-than-expected product sales from its COVID vaccine

Moderna (MRNA) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Moderna (MRNA) delivered earnings and revenue surprises of 110.73% and 60.08%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Drug, Biotech Stocks' Q1 Earnings on May 4: REGN, ZTS & More

by Kinjel Shah

Let us look at four big drug and biotech companies, REGN, ZTS, MRNA and NVO, which are gearing up for their earnings release.

Should You Buy Moderna (MRNA) Ahead of Earnings?

by Zacks Equity Research

Moderna (MRNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Vertex (VRTX) Q1 Earnings Top Estimates, Revenues Up Y/Y

by Zacks Equity Research

Vertex Pharmaceuticals' (VRTX) first-quarter 2023 earnings and sales beat estimates. Management reiterates financial guidance for 2023.